EGFR and cancer: Liposome-Fcy-hEGF does not lose discernible extent of biological activity by conjugated process at 60 °C [36], given that the cytotoxic efficiency of liposome-Fcy-hEGF/5-FC is the same as that of Fcy-hEGF/5-FC for EGFR-overexpressing cancer cells (Figure 3).